Incretin-based therapies: viewpoints on the way to consensus.

Diabetes care

Volumn 32 Suppl 2, Issue , 2009, Pages

  Nauck, Michael A ^a   Vilsbøll, Tina ^a   Gallwitz, Baptist ^a   Garber, Alan ^a   Madsbad, Sten ^a  

^a Bad Lauterberg Diabetes Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; INCRETIN;

ANIMAL; CYTOLOGY; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPOGLYCEMIA; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SECRETION;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN-SECRETING CELLS; RECEPTORS, GLUCAGON;

EID: 75549091061     PISSN: None     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-s315     Document Type: Review

References (53)